Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
CVS says GLP-1s save money when they cost less than $350 per month
Business

CVS says GLP-1s save money when they cost less than $350 per month

jack colman
By jack colman
November 16, 2026 3 Min Read
Comments Off on CVS says GLP-1s save money when they cost less than $350 per month

CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they cost less than $350 per month because reduced use of medical services, such as hospitalizations and emergency room visits, would reduce spending enough to offset drug costs.

CVS said an analysis of its Aetna insurance claims data found that among patients with obesity, diabetes or other conditions, current prices for GLP-1 drugs increase spending because they are too high to be impacted by lower medical costs.

The analysis looked at patients who were recently taking popular GLP-1 drugs – which mimic the GLP-1 hormone and reduce appetite – from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking these drugs.


A person holding weight loss injector pens including Wegovy, Ozempic and Mounjaro.
CVS Health said cheaper BPL drugs could generate savings for employers and other health plan sponsors through reduced utilization of medical services. Alliance dpa/photo via Getty Images

The drugs included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity. The analysis looked at periods of up to three years, with patients starting the drugs between 2023 and 2025.

The analysis did not break down the numbers just for obese patients.

Coverage for GLP-1 obesity drugs is declining as companies and other health plan sponsors try to reduce premiums that are expected to rise more than 9% in 2027. About 14% of companies have already dropped or plan to drop the drugs in 2027.

Zepbound and Wegovy can cost around $299 and $349 for customers paying with cash. Employers and other health plan sponsors pay between $617 and $766 per month for drugs, according to a 2025 study by the Employee Benefit Research Institute. CVS declined to comment on average prices paid.

Dr. Amy Compton-Phillips, CVS Health’s chief medical officer, said prices charged directly by drugmakers suggest they can still profit by charging less than $350 a month, while helping to lower overall health care costs. The United States pays more for health care than any other country.

“I hope we can reach that price as soon as possible,” she said in an interview before the HLTH USA conference in Las Vegas, where CVS will present the results on Sunday.


Illustration of the CVS Health logo.
Use of GLP-1 for obesity, diabetes or other conditions was associated with a 10 to 12 percent decrease in emergency room visits during the first and second years of use, according to CVS Health. REUTERS

The U.S. government struck a deal with Lilly and Novo last year to pay $245 a month for injectable GLP-1 weight-loss drugs as part of an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or disabled.

CVS said the use of GLP-1 for obesity, diabetes or other conditions was associated with a 10 to 12 percent decrease in emergency room visits during the first and second years of use. It examined the files of 60,000 people in the first year and 20,000 people in the second year.

An analysis of records of 4,000 people still taking the drug after three years showed a decrease in hospitalizations of 34 to 42 percent, according to the report.

Looking at expenses and savings over those three years, plan sponsors saved $9,400 per person in medical costs, but spent $13,300 more on prescriptions, which added costs of $3,900 per person.

The company, which also operates pharmacy benefit manager Caremark and a network of retail pharmacies it plans to create, said the price at which GLP-1s start saving money depends on the patient’s health or illness.

“An older person with diabetes will have a higher risk of hospitalization than a younger, obese person without diabetes,” Compton-Phillips said. “The higher risk the person is, the quicker you get a return on your investment.” »

Gn bussni

Views: 4
jack colman
Author

jack colman

**Jack** is a staff journalist and digital content writer at **DailyVoxa**, specializing in breaking news, technology, artificial intelligence, business, and global affairs. He is passionate about transforming complex topics into clear, accurate, and engaging stories that help readers stay informed.With a strong focus on fact-based reporting and thorough research, Jack monitors developing events, analyzes reliable sources, and delivers timely news with clarity and context. His work emphasizes accuracy, transparency, and editorial integrity while avoiding sensationalism.At DailyVoxa, every article written by Jack follows the publication's Editorial Policy, Fact-Checking Policy, and Ethics Policy. He is committed to providing trustworthy journalism that empowers readers with reliable information and meaningful insights into the stories shaping the world.

Follow Me
Other Articles
Scott Colom references viral campaign ad to criticize flight delay
Previous

Scott Colom references viral campaign ad to criticize flight delay

TSA agents find live snakes in suitcase at California airport
Next

TSA agents find live snakes in suitcase at California airport

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.